Alisertib induces G2/M arrest, apoptosis, and autophagy via PI3K/Akt/mTOR-and p38 MAPK-mediated pathways in human glioblastoma cells

American Journal of Translational Research

Volumn 9, Issue 3, 2017, Pages 845-873

  Liu, Zheng ^a,b   Wang, Feng ^a   Zhou, Zhi Wei ^b   Xia, He Chun ^a   Wang, Xin Yu ^a,b   Yang, Yin Xue ^a   He, Zhi Xu ^c   Sun, Tao ^a   Zhou, Shu Feng ^b,d  

^a NINGXIA MEDICAL UNIVERSITY   (China)

^b UNIVERSITY OF SOUTH FLORIDA   (United States)

^c GUIZHOU MEDICAL UNIVERSITY   (China)

^d HUAQIAO UNIVERSITY   (China)

Author keywords

Alisertib; Apoptosis; Aurora kinase A; Aurora kinase B; Autophagy; Cell cycle; DAOY cell; Glioblastoma; Hydrogen bond; Molecular docking; PI3K Akt mTOR pathway

Indexed keywords

ALISERTIB; AURORA B KINASE; BARASERTIB; BECLIN 1; CASPASE 3; CYCLIN B1; CYCLIN DEPENDENT KINASE 1; CYCLIN DEPENDENT KINASE 2; CYCLIN DEPENDENT KINASE INHIBITOR 1B; CYTOCHROME C; DANUSERTIB; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE KINASE; MAMMALIAN TARGET OF RAPAMYCIN; MITOGEN ACTIVATED PROTEIN KINASE P38; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN BAX; PROTEIN BCL 2; PROTEIN BCL XL; PROTEIN KINASE B; PROTEIN P53; SYNAPTOPHYSIN; TOZASERTIB;

APOPTOSIS; ARTICLE; AUTOPHAGY; CELL CULTURE; CELL CYCLE; CELL CYCLE ARREST; CELL PROLIFERATION; CELL VIABILITY ASSAY; CONTROLLED STUDY; FLOW CYTOMETRY; FLUORESCENCE MICROSCOPY; GLIOBLASTOMA; HUMAN; HUMAN CELL; HYDROGEN BOND; MOLECULAR DOCKING; MOLECULAR INTERACTION; MTT ASSAY; PHOSPHORYLATION; PROTEIN EXPRESSION; SIGNAL TRANSDUCTION; WESTERN BLOTTING;

EID: 85016437357     PISSN: None     EISSN: 19438141     Source Type: Journal    
DOI: None     Document Type: Article

References (80)

1. Torre LA, Bray F, Siegel RL, Ferlay J, Lortet-Tieulent J and Jemal A. Global cancer statistics, 2012. CA Cancer J Clin 2015; 65: 87-108.
2. Siegel R, Naishadham D and Jemal A. Cancer statistics, 2013. CA Cancer J Clin 2013; 63: 11-30.
3. Siegel RL, Miller KD and Jemal A. Cancer statistics, 2017. CA Cancer J Clin 2017; 67: 7-30.
4. Omuro A and DeAngelis LM. Glioblastoma and other malignant gliomas: a clinical review. JAMA 2013; 310: 1842-1850.
5. Wirsching HG, Galanis E and Weller M. Glioblastoma. Handb Clin Neurol 2016; 134: 381-397.
6. Mesti T and Ocvirk J. Malignant gliomas: old and new systemic treatment approaches. Radiol Oncol 2016; 50: 129-138.
7. de Groot JF. High-grade gliomas. Continuum (Minneap Minn) 2015; 21: 332-344.
8. Kumthekar P, Raizer J and Singh S. Low-grade glioma. Cancer Treat Res 2015; 163: 75-87.
9. Woehrer A, Bauchet L and Barnholtz-Sloan JS. Glioblastoma survival: has it improved? Evidence from population-based studies. Curr Opin Neurol 2014; 27: 666-674.
10. Lapenna S and Giordano A. Cell cycle kinases as therapeutic targets for cancer. Nat Rev Drug Discov 2009; 8: 547-566.
11. Pitts TM, Davis SL, Eckhardt SG and Bradshaw-Pierce EL. Targeting nuclear kinases in cancer: development of cell cycle kinase inhibitors. Pharmacol Ther 2014; 142: 258-269.
12. Dominguez-Brauer C, Thu KL, Mason JM, Blaser H, Bray MR and Mak TW. Targeting mitosis in cancer: emerging strategies. Mol Cell 2015; 60: 524-536.
13. Sampath SC, Ohi R, Leismann O, Salic A, Pozniakovski A and Funabiki H. The chromosomal passenger complex is required for chromatin-induced microtubule stabilization and spindle assembly. Cell 2004; 118: 187-202.
14. Krenn V and Musacchio A. The Aurora B kinase in chromosome bi-orientation and spindle checkpoint signaling. Front Oncol 2015; 5: 225.
15. Cicenas J and Cicenas E. Multi-kinase inhibitors, AURKs and cancer. Med Oncol 2016; 33: 43.
16. Dar AA, Goff LW, Majid S, Berlin J and El-Rifai W. Aurora kinase inhibitors-rising stars in cancer therapeutics? Mol Cancer Ther 2010; 9: 268-278.
17. Hirota T, Kunitoku N, Sasayama T, Marumoto T, Zhang D, Nitta M, Hatakeyama K and Saya H. Aurora-A and an interacting activator, the LIM protein Ajuba, are required for mitotic commitment in human cells. Cell 2003; 114: 585-598.
18. Yan M, Wang C, He B, Yang M, Tong M, Long Z, Liu B, Peng F, Xu L, Zhang Y, Liang D, Lei H, Subrata S, Kelley KW, Lam EW, Jin B and Liu Q. Aurora-A kinase: a potent oncogene and target for cancer therapy. Med Res Rev 2016; 36: 1036-1079.
19. Lehman NL, O’Donnell JP, Whiteley LJ, Stapp RT, Lehman TD, Roszka KM, Schultz LR, Williams CJ, Mikkelsen T, Brown SL, Ecsedy JA and Poisson LM. Aurora A is differentially expressed in gliomas, is associated with patient survival in glioblastoma and is a potential chemotherapeutic target in gliomas. Cell Cycle 2012; 11: 489-502.
20. Durlacher CT, Li ZL, Chen XW, He ZX and Zhou SF. An update on the pharmacokinetics and pharmacodynamics of alisertib, a selective Aurora kinase A inhibitor. Clin Exp Pharmacol Physiol 2016; 43: 585-601.
21. Ding YH, Zhou ZW, Ha CF, Zhang XY, Pan ST, He ZX, Edelman JL, Wang D, Yang YX, Zhang X, Duan W, Yang T, Qiu JX and Zhou SF. Alisertib, an Aurora kinase A inhibitor, induces apoptosis and autophagy but inhibits epithelial to mesenchymal transition in human epithelial ovarian cancer cells. Drug Des Devel Ther 2015; 9: 425-464.
22. Yuan CX, Zhou ZW, Yang YX, He ZX, Zhang X, Wang D, Yang T, Wang NJ, Zhao RJ and Zhou SF. Inhibition of mitotic Aurora kinase A by alisertib induces apoptosis and autophagy of human gastric cancer AGS and NCI-N78 cells. Drug Des Devel Ther 2015; 9: 487-508.
23. Wang F, Li H, Yan XG, Zhou ZW, Yi ZG, He ZX, Pan ST, Yang YX, Wang ZZ, Zhang X, Yang T, Qiu JX and Zhou SF. Alisertib induces cell cycle arrest and autophagy and suppresses epithelial-to-mesenchymal transition involving PI3K/Akt/ mTOR and sirtuin 1-mediated signaling pathways in human pancreatic cancer cells. Drug Des Devel Ther 2015; 9: 575-601.
24. Li JP, Yang YX, Liu QL, Pan ST, He ZX, Zhang X, Yang T, Chen XW, Wang D, Qiu JX and Zhou SF. The investigational Aurora kinase A inhibitor alisertib (MLN8237) induces cell cycle G2/M arrest, apoptosis, and autophagy via p38 MAPK and Akt/mTOR signaling pathways in human breast cancer cells. Drug Des Devel Ther 2015; 9: 1627-1652.
25. Niu NK, Wang ZL, Pan ST, Ding HQ, Au GH, He ZX, Zhou ZW, Xiao G, Yang YX, Zhang X, Yang T, Chen XW, Qiu JX and Zhou SF. Pro-apoptotic and pro-autophagic effects of the Aurora kinase A inhibitor alisertib (MLN8237) on human osteosarcoma U-2 OS and MG-63 cells through the activation of mitochondria-mediated pathway and inhibition of p38 MAPK/PI3K/ Akt/mTOR signaling pathway. Drug Des Devel Ther 2015; 9: 1555-1584.
26. Shu LP, Zhou ZW, Zi D, He ZX and Zhou SF. A SILAC-based proteomics elicits the molecular interactome of alisertib (MLN8237) in human erythroleukemia K562 cells. Am J Transl Res 2015; 7: 2442-2461.
27. Ren BJ, Zhou ZW, Zhu DJ, Ju YL, Wu JH, Ouyang MZ, Chen XW and Zhou SF. Alisertib induces cell cycle arrest, apoptosis, autophagy and suppresses EMT in HT29 and Caco-2 cells. Int J Mol Sci 2015; 17: 41.
28. Wang ZX, Sun J, Howell CE, Zhou QY, He ZX, Yang T, Chew H, Duan W, Zhou ZW, Kanwar JR and Zhou SF. Prediction of the likelihood of drug interactions with kinase inhibitors based on in vitro and computational studies. Fundam Clin Pharmacol 2014; 28: 551-582.
29. Yin JJ, Sharma S, Shumyak SP, Wang ZX, Zhou ZW, Zhang Y, Guo P, Li CZ, Kanwar JR, Yang T, Mohapatra SS, Liu W, Duan W, Wang JC, Li Q, Zhang X, Tan J, Jia L, Liang J, Wei MQ, Li X and Zhou SF. Synthesis and biological evaluation of novel folic acid receptor-targeted, beta-cyclodextrin-based drug complexes for cancer treatment. PLoS One 2013; 8: e62289.
30. Liu YH, Mo SL, Bi HC, Hu BF, Li CG, Wang YT, Huang L, Huang M, Duan W, Liu JP, Wei MQ and Zhou SF. Regulation of human pregnane X receptor and its target gene cytochrome P450 3A4 by Chinese herbal compounds and a molecular docking study. Xenobiotica 2011; 41: 259-280.
31. Mo SL, Liu WF, Chen Y, Luo HB, Sun LB, Chen XW, Zhou ZW, Sneed KB, Li CG, Du YM, Liang J and Zhou SF. Ligand-and protein-based modeling studies of the inhibitors of human cytochrome P450 2D6 and a virtual screening for potential inhibitors from the Chinese herbal medicine, Scutellaria baicalensis (Huangqin, Baikal Skullcap). Comb Chem High Throughput Screen 2012; 15: 36-80.
32. Yang LP, Zhou ZW, Chen XW, Li CG, Sneed KB, Liang J and Zhou SF. Computational and in vitro studies on the inhibitory effects of herbal compounds on human cytochrome P450 1A2. Xenobiotica 2012; 42: 238-255.
33. Mo SL, Liu WF, Li CG, Zhou ZW, Luo HB, Chew H, Liang J and Zhou SF. Pharmacophore, QSAR, and binding mode studies of substrates of human cytochrome P450 2D6 (CYP2D6) using molecular docking and virtual mutations and an application to chinese herbal medicine screening. Curr Pharm Biotechnol 2012; 13: 1640-1704.
34. Su J, Chang C, Xiang Q, Zhou ZW, Luo R, Yang L, He ZX, Yang H, Li J, Bei Y, Xu J, Zhang M, Zhang Q, Su Z, Huang Y, Pang J and Zhou SF. Xyloketal B, a marine compound, acts on a network of molecular proteins and regulates the activity and expression of rat cytochrome P450 3a: a bioinformatic and animal study. Drug Des Devel Ther 2014; 8: 2555-2602.
35. Qiu JX, Zhou ZW, He ZX, Zhang X, Zhou SF and Zhu S. Estimation of the binding modes with important human cytochrome P450 enzymes, drug interaction potential, pharmacokinetics, and hepatotoxicity of ginger components using molecular docking, computational, and phar macokinetic modeling studies. Drug Des Devel Ther 2015; 9: 841-866.
36. Han XD, Zhou ZW, Yang W, Ye HC, Xu YZ, Huang YF, Zhang T and Zhou SF. A computational and functional study elicits the ameliorating effect of the Chinese herbal formula Huo Luo Xiao Ling Dan on experimental ischemia-induced myocardial injury in rats via inhibition of apoptosis. Drug Des Devel Ther 2015; 9: 1063-1102.
37. Qiu JX, Zhou ZW, He ZX, Zhao RJ, Zhang X, Yang L, Zhou SF and Mao ZF. Plumbagin elicits differential proteomic responses mainly involving cell cycle, apoptosis, autophagy, and epithelial-to-mesenchymal transition pathways in human prostate cancer PC-3 and DU145 cells. Drug Des Devel Ther 2015; 9: 349-417.
38. Li YC, He SM, He ZX, Li M, Yang Y, Pang JX, Zhang X, Chow K, Zhou Q, Duan W, Zhou ZW, Yang T, Huang GH, Liu A, Qiu JX, Liu JP and Zhou SF. Plumbagin induces apoptotic and autophagic cell death through inhibition of the PI3K/Akt/mTOR pathway in human non-small cell lung cancer cells. Cancer Lett 2014; 344: 239-259.
39. Balan M and Pal S. A novel CXCR3-B chemokine receptor-induced growth-inhibitory signal in cancer cells is mediated through the regulation of Bach-1 protein and Nrf2 protein nuclear translocation. J Biol Chem 2014; 289: 3126-3137.
40. Do TV, Xiao F, Bickel LE, Klein-Szanto AJ, Pathak HB, Hua X, Howe C, O’Brien SW, Maglaty M, Ecsedy JA, Litwin S, Golemis EA, Schilder RJ, Godwin AK and Connolly DC. Aurora kinase A mediates epithelial ovarian cancer cell migration and adhesion. Oncogene 2014; 33: 539-549.
41. Baig MH, Ahmad K, Roy S, Ashraf JM, Adil M, Siddiqui MH, Khan S, Kamal MA, Provaznik I and Choi I. Computer aided drug design: success and limitations. Curr Pharm Des 2016; 22: 572-581.
42. Manfredi MG, Ecsedy JA, Chakravarty A, Silverman L, Zhang M, Hoar KM, Stroud SG, Chen W, Shinde V, Huck JJ, Wysong DR, Janowick DA, Hyer ML, Leroy PJ, Gershman RE, Silva MD, Germanos MS, Bolen JB, Claiborne CF and Sells TB. Characterization of Alisertib (MLN8237), an investigational small-molecule inhibitor of aurora A kinase using novel in vivo pharmacodynamic assays. Clin Cancer Res 2011; 17: 7614-7624.
43. Manfredi MG, Ecsedy JA, Meetze KA, Balani SK, Burenkova O, Chen W, Galvin KM, Hoar KM, Huck JJ, LeRoy PJ, Ray ET, Sells TB, Stringer B, Stroud SG, Vos TJ, Weatherhead GS, Wysong DR, Zhang M, Bolen JB and Claiborne CF. Antitumor activity of MLN8054, an orally active small-molecule inhibitor of Aurora A kinase. Proc Natl Acad Sci U S A 2007; 104: 4106-4111.
44. Yang J, Ikezoe T, Nishioka C, Tasaka T, Taniguchi A, Kuwayama Y, Komatsu N, Bandobashi K, Togitani K, Koeffler HP, Taguchi H and Yokoyama A. AZD1152, a novel and selective aurora B kinase inhibitor, induces growth arrest, apoptosis, and sensitization for tubulin depolymerizing agent or topoisomerase II inhibitor in human acute leukemia cells in vitro and in vivo. Blood 2007; 110: 2034-2040.
45. Wang S, Midgley CA, Scaerou F, Grabarek JB, Griffiths G, Jackson W, Kontopidis G, McClue SJ, McInnes C, Meades C, Mezna M, Plater A, Stuart I, Thomas MP, Wood G, Clarke RG, Blake DG, Zheleva DI, Lane DP, Jackson RC, Glover DM and Fischer PM. Discovery of N-phenyl-4-(thiazol-5-yl)pyrimidin-2-amine aurora kinase inhibitors. J Med Chem 2010; 53: 4367-4378.
46. Payton M, Bush TL, Chung G, Ziegler B, Eden P, McElroy P, Ross S, Cee VJ, Deak HL, Hodous BL, Nguyen HN, Olivieri PR, Romero K, Schenkel LB, Bak A, Stanton M, Dussault I, Patel VF, Geuns-Meyer S, Radinsky R and Kendall RL. Preclinical evaluation of AMG 900, a novel potent and highly selective pan-aurora kinase inhibitor with activity in taxane-resistant tumor cell lines. Cancer Res 2010; 70: 9846-9854.
47. Harrington EA, Bebbington D, Moore J, Rasmussen RK, Ajose-Adeogun AO, Nakayama T, Graham JA, Demur C, Hercend T, Diu-Hercend A, Su M, Golec JM and Miller KM. VX-680, a potent and selective small-molecule inhibitor of the Aurora kinases, suppresses tumor growth in vivo. Nat Med 2004; 10: 262-267.
48. Sarvagalla S and Coumar MS. Structural biology insight for the design of sub-type selective Aurora kinase inhibitors. Curr Cancer Drug Targets 2015; 15: 375-393.
49. Elkins JM, Santaguida S, Musacchio A and Knapp S. Crystal structure of human aurora B in complex with INCENP and VX-680. J Med Chem 2012; 55: 7841-7848.
50. Littlepage LE, Wu H, Andresson T, Deanehan JK, Amundadottir LT and Ruderman JV. Identification of phosphorylated residues that affect the activity of the mitotic kinase Aurora-A. Proc Natl Acad Sci U S A 2002; 99: 15440-15445.
51. Cheetham GM, Knegtel RM, Coll JT, Renwick SB, Swenson L, Weber P, Lippke JA and Austen DA. Crystal structure of aurora-2, an oncogenic serine/threonine kinase. J Biol Chem 2002; 277: 42419-42422.
52. Kohrman AQ and Matus DQ. Divide or conquer: cell cycle regulation of invasive behavior. Trends Cell Biol 2017; 27: 12-25.
53. Peng CY, Graves PR, Thoma RS, Wu Z, Shaw AS and Piwnica-Worms H. Mitotic and G2 checkpoint control: regulation of 14-3-3 protein binding by phosphorylation of Cdc25C on serine-216. Science 1997; 277: 1501-1505.
54. Wang TH, Wang HS and Soong YK. Paclitaxel-induced cell death: where the cell cycle and apoptosis come together. Cancer 2000; 88: 2619-2628.
55. Yoon MK, Mitrea DM, Ou L and Kriwacki RW. Cell cycle regulation by the intrinsically disordered proteins p21 and p27. Biochem Soc Trans 2012; 40: 981-988.
56. Carvajal LA and Manfredi JJ. Another fork in the road-life or death decisions by the tumour suppressor p53. EMBO Rep 2013; 14: 414-421.
57. Pitts TM, Bradshaw-Pierce EL, Bagby SM, Hyatt SL, Selby HM, Spreafico A, Tentler JJ, McPhillips K, Klauck PJ, Capasso A, Diamond JR, Davis SL, Tan AC, Arcaroli JJ, Purkey A, Messersmith WA, Ecsedy JA and Eckhardt SG. Antitumor activity of the aurora a selective kinase inhibitor, alisertib, against preclinical models of colorectal cancer. Oncotarget 2016; 7: 50290-50301.
58. Ouyang L, Shi Z, Zhao S, Wang FT, Zhou TT, Liu B and Bao JK. Programmed cell death pathways in cancer: a review of apoptosis, autophagy and programmed necrosis. Cell Prolif 2012; 45: 487-498.
59. Estaquier J, Vallette F, Vayssiere JL and Mignotte B. The mitochondrial pathways of apoptosis. Adv Exp Med Biol 2012; 942: 157-183.
60. Logue SE and Martin SJ. Caspase activation cascades in apoptosis. Biochem Soc Trans 2008; 36: 1-9.
61. Li P, Nijhawan D, Budihardjo I, Srinivasula SM, Ahmad M, Alnemri ES and Wang X. Cytochrome c and dATP-dependent formation of Apaf-1/ caspase-9 complex initiates an apoptotic protease cascade. Cell 1997; 91: 479-489.
62. Czabotar PE, Lessene G, Strasser A and Adams JM. Control of apoptosis by the BCL-2 protein family: implications for physiology and therapy. Nat Rev Mol Cell Biol 2014; 15: 49-63.
63. Taylor RC, Cullen SP and Martin SJ. Apoptosis: controlled demolition at the cellular level. Nat Rev Mol Cell Biol 2008; 9: 231-241.
64. Grasso D, Garcia MN and Iovanna JL. Autophagy in pancreatic cancer. Int J Cell Biol 2012; 2012: 760498.
65. Yang S and Kimmelman AC. A critical role for autophagy in pancreatic cancer. Autophagy 2011; 7: 912-913.
66. Yang MC, Loh JK, Li YY, Huang WS, Chou CH, Cheng JT, Wang YT, Lieu AS, Howng SL, Hong YR and Chou AK. Bcl2L12 with a BH3-like domain in regulating apoptosis and TMZ-induced autophagy: a prospective combination of ABT-737 and TMZ for treating glioma. Int J Oncol 2015; 46: 1304-1316.
67. Catalano M, D’Alessandro G, Lepore F, Corazzari M, Caldarola S, Valacca C, Faienza F, Esposito V, Limatola C, Cecconi F and Di Bartolomeo S. Autophagy induction impairs migration and invasion by reversing EMT in glioblastoma cells. Mol Oncol 2015; 9: 1612-1625.
68. Rajagopalan V, Vaidyanathan M, Janardhanam VA and Bradner JE. Pre-clinical analysis of changes in intra-cellular biochemistry of glioblastoma multiforme (GBM) cells due to c-Myc silencing. Cell Mol Neurobiol 2014; 34: 1059-1069.
69. Rodon J, Dienstmann R, Serra V and Tabernero J. Development of PI3K inhibitors: lessons learned from early clinical trials. Nat Rev Clin Oncol 2013; 10: 143-153.
70. Porta C, Paglino C and Mosca A. Targeting PI3K/Akt/mTOR signaling in cancer. Front Oncol 2014; 4: 64.
71. Melaiu O, Cristaudo A, Melissari E, Di Russo M, Bonotti A, Bruno R, Foddis R, Gemignani F, Pellegrini S and Landi S. A review of transcriptome studies combined with data mining reveals novel potential markers of malignant pleural mesothelioma. Mutat Res 2012; 750: 132-140.
72. Rabinowitz JD and White E. Autophagy and metabolism. Science 2010; 330: 1344-1348.
73. Dunlop EA and Tee AR. The kinase triad, AMPK, mTORC1 and ULK1, maintains energy and nutrient homoeostasis. Biochem Soc Trans 2013; 41: 939-943.
74. Denton D, Nicolson S and Kumar S. Cell death by autophagy: facts and apparent artefacts. Cell Death Differ 2012; 19: 87-95.
75. Arthur JS and Ley SC. Mitogen-activated protein kinases in innate immunity. Nat Rev Immunol 2013; 13: 679-692.
76. Koul HK, Pal M and Koul S. Role of p38 MAP kinase signal transduction in solid tumors. Genes Cancer 2013; 4: 342-359.
77. Wang W, Fan H, Zhou Y, Duan P, Zhao G and Wu G. Knockdown of autophagy-related gene BECLIN1 promotes cell growth and inhibits apoptosis in the A549 human lung cancer cell line. Mol Med Rep 2013; 7: 1501-1505.
78. Mester J and Eng C. When overgrowth bumps into cancer: the PTEN-opathies. Am J Med Genet C Semin Med Genet 2013; 163C: 114-121.
79. Kurokawa C, Geekiyanage H, Allen C, Iankov I, Schroeder M, Carlson B, Bakken K, Sarkaria J, Ecsedy JA, D’Assoro A, Friday B and Galanis E. Alisertib demonstrates significant antitumor activity in bevacizumab resistant, patient derived orthotopic models of glioblastoma. J Neurooncol 2017; 131: 41-48.
80. Daniele S, Sestito S, Pietrobono D, Giacomelli C, Chiellini G, Di Maio D, Marinelli L, Novellino E, Martini C and Rapposelli S. Dual inhibition of PDK1 and Aurora kinase A: an effective strategy to induce differentiation and apoptosis of human glioblastoma multiforme stem cells. ACS Chem Neurosci 2017; 8: 100-114.